300 related articles for article (PubMed ID: 10926799)
21. Secondary cytoreductive surgery in patients presenting with isolated nodal recurrence of epithelial ovarian cancer.
Fotiou S; Aliki T; Petros Z; Ioanna S; Konstantinos V; Vasiliki M; George C
Gynecol Oncol; 2009 Aug; 114(2):178-82. PubMed ID: 19450872
[TBL] [Abstract][Full Text] [Related]
22. Prognostic factors for surgical outcome and survival in 447 women treated for advanced (FIGO-stages III-IV) epithelial ovarian carcinoma.
Skírnisdóttir I; Sorbe B
Int J Oncol; 2007 Mar; 30(3):727-34. PubMed ID: 17273775
[TBL] [Abstract][Full Text] [Related]
23. Procedures required to accomplish complete cytoreduction of ovarian cancer: is there a correlation with "biological aggressiveness" and survival?
Eisenkop SM; Spirtos NM
Gynecol Oncol; 2001 Sep; 82(3):435-41. PubMed ID: 11520137
[TBL] [Abstract][Full Text] [Related]
24. [Treatment and prognostic factors for stage IV epithelial ovarian cancer].
Wu M; Shen K; Lang J
Zhonghua Fu Chan Ke Za Zhi; 2000 Apr; 35(4):200-3. PubMed ID: 11776158
[TBL] [Abstract][Full Text] [Related]
25. Analysis of FIGO Stage IIIc endometrial cancer patients.
McMeekin DS; Lashbrook D; Gold M; Johnson G; Walker JL; Mannel R
Gynecol Oncol; 2001 May; 81(2):273-8. PubMed ID: 11330962
[TBL] [Abstract][Full Text] [Related]
26. Analysis of treatment failures and survival of patients with fallopian tube carcinoma: a cooperation task force (CTF) study.
Gadducci A; Landoni F; Sartori E; Maggino T; Zola P; Gabriele A; Rossi R; Cosio S; Fanucchi A; Tisi G
Gynecol Oncol; 2001 May; 81(2):150-9. PubMed ID: 11330942
[TBL] [Abstract][Full Text] [Related]
27. Preoperative hyperfractionated chemoradiation for locally recurrent rectal cancer in patients previously irradiated to the pelvis: A multicentric phase II study.
Valentini V; Morganti AG; Gambacorta MA; Mohiuddin M; Doglietto GB; Coco C; De Paoli A; Rossi C; Di Russo A; Valvo F; Bolzicco G; Dalla Palma M;
Int J Radiat Oncol Biol Phys; 2006 Mar; 64(4):1129-39. PubMed ID: 16414206
[TBL] [Abstract][Full Text] [Related]
28. Outcome of ovarian cancer patients who underwent incomplete surgical staging.
Panprom P; Lertkhachonsuk R
J Med Assoc Thai; 2008 Sep; 91(9):1323-30. PubMed ID: 18843859
[TBL] [Abstract][Full Text] [Related]
29. p53 overexpression is associated with cytoreduction and response to chemotherapy in ovarian cancer.
Ferrandina G; Fagotti A; Salerno MG; Natali PG; Mottolese M; Maneschi F; De Pasqua A; Benedetti-Panici P; Mancuso S; Scambia G
Br J Cancer; 1999 Oct; 81(4):733-40. PubMed ID: 10574264
[TBL] [Abstract][Full Text] [Related]
30. Pelvic lymph node count is an important prognostic variable for FIGO stage I and II endometrial carcinoma with high-risk histology.
Lutman CV; Havrilesky LJ; Cragun JM; Secord AA; Calingaert B; Berchuck A; Clarke-Pearson DL; Soper JT
Gynecol Oncol; 2006 Jul; 102(1):92-7. PubMed ID: 16406063
[TBL] [Abstract][Full Text] [Related]
31. Primary and metastatic ovarian cancer in patients with prior breast carcinoma. Pre-operative markers and treatment results.
Tserkezoglou A; Kontou S; Hadjieleftheriou G; Apostolikas N; Vassilomanolakis M; Sikiotis K; Salamalekis E; Tseke P; Magiakos G
Anticancer Res; 2006; 26(3B):2339-44. PubMed ID: 16821613
[TBL] [Abstract][Full Text] [Related]
32. Lymph node metastasis in stage I epithelial ovarian cancer.
Suzuki M; Ohwada M; Yamada T; Kohno T; Sekiguchi I; Sato I
Gynecol Oncol; 2000 Nov; 79(2):305-8. PubMed ID: 11063662
[TBL] [Abstract][Full Text] [Related]
33. Stage II endometrioid adenocarcinoma of the endometrium: clinical implications of cervical stromal invasion.
Orezzoli JP; Sioletic S; Olawaiye A; Oliva E; del Carmen MG
Gynecol Oncol; 2009 Jun; 113(3):316-23. PubMed ID: 19345400
[TBL] [Abstract][Full Text] [Related]
34. Endometriosis-associated ovarian carcinoma (EAOC): an entity distinct from other ovarian carcinomas as suggested by a nested case-control study.
Erzen M; Rakar S; Klancnik B; Syrjänen K
Gynecol Oncol; 2001 Oct; 83(1):100-8. PubMed ID: 11585420
[TBL] [Abstract][Full Text] [Related]
35. Tumor residual after surgical cytoreduction in prediction of clinical outcome in stage IV epithelial ovarian cancer: a Gynecologic Oncology Group Study.
Winter WE; Maxwell GL; Tian C; Sundborg MJ; Rose GS; Rose PG; Rubin SC; Muggia F; McGuire WP;
J Clin Oncol; 2008 Jan; 26(1):83-9. PubMed ID: 18025437
[TBL] [Abstract][Full Text] [Related]
36. Secondary cytoreductive surgery for isolated nodal recurrence in patients with epithelial ovarian cancer.
Santillan A; Karam AK; Li AJ; Giuntoli R; Gardner GJ; Cass I; Karlan BY; Bristow RE
Gynecol Oncol; 2007 Mar; 104(3):686-90. PubMed ID: 17141302
[TBL] [Abstract][Full Text] [Related]
37. Should pelvic and para-aortic lymphadenectomy be different depending on histological subtype in epithelial ovarian cancer?
Roger N; Zafrani Y; Uzan C; Gouy S; Rey A; Pautier P; Lhommé C; Duvillard P; Castaigne D; Morice P
Ann Surg Oncol; 2008 Jan; 15(1):333-8. PubMed ID: 17943386
[TBL] [Abstract][Full Text] [Related]
38. Lymphatic spread among women with primary peritoneal carcinoma.
Eltabbakh GH; Mount SL
J Surg Oncol; 2002 Nov; 81(3):126-31. PubMed ID: 12407724
[TBL] [Abstract][Full Text] [Related]
39. Prognostic importance of preoperative CA-125 in International Federation of Gynecology and Obstetrics stage I epithelial ovarian cancer: an Australian multicenter study.
Paramasivam S; Tripcony L; Crandon A; Quinn M; Hammond I; Marsden D; Proietto A; Davy M; Carter J; Nicklin J; Perrin L; Obermair A
J Clin Oncol; 2005 Sep; 23(25):5938-42. PubMed ID: 16087942
[TBL] [Abstract][Full Text] [Related]
40. Twenty-five year outcome of sequential abdominal radiotherapy and melphalan:implications for future management of epithelial carcinoma of the ovary.
Dusenbery KE; Bellairs EE; Potish RA; Twiggs LB; Boente MP
Gynecol Oncol; 2005 Feb; 96(2):307-13. PubMed ID: 15661213
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
